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ABSTRACT
Background: In 2015, 5.3 million babies died in the
third trimester of pregnancy and first month following
birth. Progress in reducing neonatal mortality and
stillbirth rates has lagged behind the substantial
progress in reducing postneonatal and maternal
mortality rates. The benefits to prenatal and neonatal
health (PNH) from maternal and child health
investments cannot be assumed.
Methods: We analysed donor funding for PNH over
the period 2003–2013. We used an exhaustive key
term search followed by manual review and
classification to identify official development
assistance and private grant (ODA+)
disbursement records in the Countdown to 2015
ODA+ Database.
Results: The value of ODA+ mentioning PNH or an
activity that would directly benefit PNH increased
from $105 million in 2003 to $1465 million in 2013,
but this included a 3% decline between 2012 and
2013. Projects exclusively benefitting PNH reached
just $6 million in 2013. Records mentioning PNH
accounted for 3% of the $2708 million disbursed in
2003 for maternal, newborn and child health
(MNCH) and increased to 13% of the $9287 million
disbursed for MNCH in 2013. In 11 years, only nine
records ($6 million) mentioned stillbirth,
miscarriage, or the fetus, although the two leading
infectious causes of stillbirth were mentioned in
records worth $832 million. The USA disbursed the
most ODA+ mentioning PNH ($2848 million, 40% of
the total) and Unicef disbursed the most ODA+
exclusively benefitting PNH ($18 million, 30%).
We found evidence that funding mentioning and
exclusively benefitting PNH was targeted to
countries with greater economic needs, but the
evidence of targeting to health needs was weak and
inconsistent.
Conclusions: Newborn health rose substantially on
the global agenda between 2003 and 2013, but
prenatal health received minimal attention in donor
funding decisions. Declines in 2013 and
persistently low funding exclusively benefitting
PNH indicate a need for caution and
continued monitoring of donors’ support for
newborn health.
Key questions
What is already known about this topic?
▸ Progress has been made in reducing the global
stillbirth rate and the neonatal mortality rate, but
their average annual rates of reduction have
lagged behind those for maternal mortality and
for under-5 child mortality.
▸ Previous analyses tracked donor funding for
newborns and stillbirth up to 2010 and briefly
reported on the 75 Countdown priority countries
up to 2012 and on stillbirths globally up to
2013. They found increasing attention for
newborn health, but not stillbirths.
What are the new findings?
▸ Using updated data sources and methods, we
found that funding mentioning prenatal and neo-
natal health (PNH) from 52 donors to 156 recipi-
ent countries increased substantially between
2003 and 2013 in absolute terms and relative to
funding for maternal, newborn and child health
(MNCH) as a whole. However, funding mention-
ing PNH and exclusively benefitting PNH
decreased in 2013, even though funding for
MNCH increased substantially. Funding exclu-
sively benefitting PNH remained extremely low.
▸ The USA disbursed the most funding mention-
ing PNH over the 11-year period ($2848 million,
40%), followed by Canada ($1198 million, 17%)
and the International Development Association
(World Bank, $585 million, 8%). Unicef dis-
bursed the most funding exclusively benefitting
PNH ($18 million), followed by the USA ($15
million) and Japan ($5 million).
▸ There was some evidence that funding was tar-
geted to countries with greater health and eco-
nomic need; however, other factors explain
much of the substantial variation in funding
between recipient countries.
▸ Babies’ prenatal health was rarely mentioned in
funding descriptions. Malaria in pregnancy and
syphilis were mentioned in funding worth $832
million, but these projects rarely mentioned still-
birth, even though programmes addressing
these diseases may make their greatest impact
through stillbirth prevention.
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INTRODUCTION
In 2015, 2.6 million babies were stillborn1 and a further
2.7 million died as newborns in their ﬁrst 28 days after
birth.2 While progress has been made in reducing the
global stillbirth rate (SBR) and the neonatal mortality
rate (NMR), their average annual rates of reduction
have lagged behind those for maternal mortality and for
under-5 child mortality, which were targeted in the
Millennium Development Goals (MDGs). Between 2000
and 2015, the maternal mortality ratio fell by 37%3 while
the SBR, which is rarely measured in national statistics
and was omitted from the MDGs,4 is estimated to have
fallen by a more modest 26%.1 Over the same period,
the postneonatal mortality rate fell by 50%, while the
NMR fell by 38%.2 By 2015, newborns accounted for
45% of all deaths in children under 5.2 Beyond survival,
the growing research ﬁeld of life course epidemiology
highlights proliferating evidence on the degree to which
fetal and neonatal health affects lifelong health out-
comes, notably preventing disability, improving child
development and reducing the risk of adult-onset non-
communicable diseases.5 Promoting the health of babies
before, during, and in the ﬁrst month after birth is there-
fore an urgent global health challenge, which requires
speciﬁc attention within the continuum of care and
the broader reproductive, maternal, and child health
agenda throughout the Sustainability Development Goals
(SDG) era.4 6
Donor funding and attention may have been among
the factors that contributed to the substantial declines in
child and maternal mortality.7 Between 2003 and 2013,
donor funding for child health and for maternal and
newborn health increased by 286% and 164%, respect-
ively.8 In many low-income and lower-middle-income
countries, donor funding constitutes a substantial
proportion of overall health spending.9 Even in
upper-middle-income countries and others where domes-
tic resources account for the vast majority of health
expenditure, donor funding may catalyse efforts for
issues that might otherwise receive little attention.
Estimating the full value of aid that promotes a speciﬁc
health priority is, however, challenging, because funding
directed towards a speciﬁc disease or health system
challenge will beneﬁt various population groups, not all
of which would or could necessarily be described
(let alone quantiﬁed) in reports of that funding. The
value of donor funding speciﬁcally mentioning particular
issues can, however, serve as a quantitative metric of
change in the status of issues on global policy agendas10
and can inform estimates of the minimum value of aid
actually supporting a given health priority. Tracking the
value of aid for health priorities is therefore important
for holding governments and donors accountable, for
assessing the degree to which speciﬁc health issues have
gained or lost traction on the global agenda, and for indi-
cating whether there may be a substantial mismatch
between investment levels and burden of ill health.
In this article, we analyse donor funding for prenatal
and neonatal health (PNH) over the period 2003–2013.
Following Froen et al,11 we use the term ‘prenatal
health’ to refer to the health of babies before and
during birth. Our analysis extends, updates and further
analyses previous work to track donor funding for new-
borns and stillbirths, which we originally conducted for
funding up to 201012 and reported on brieﬂy for the 75
Countdown priority countries up to 201213 and globally
for stillbirths up to 2013.11 In particular, this new analysis
explicitly includes neonatal health and stillbirth preven-
tion, involves improved methods for identifying funding
mentioning PNH, accounts for unspeciﬁed recipients
and regional disbursements within country-speciﬁc
estimates, and is applied to a larger, updated data set for
an 11-year period. With these advances, we are now able
to better assess trends and the degree to which donor
aid was targeted to need.14 We compare the value of
funding mentioning PNH with estimates of the total
value of donor funding beneﬁtting maternal, newborn
and child health (MNCH) to indicate whether PNH has
gained or lost traction within MNCH and to provide
lower and upper bounds for estimates of the total value
of donor funding which may actually beneﬁt PNH.
Finally, we examine key themes within donors’ reporting
of their funding mentioning PNH and focus particularly
on malaria and syphilis in pregnancy, which are leading
infectious causes of miscarriage and stillbirth and con-
tribute to poor neonatal health.1
METHODS
Data source
We identiﬁed disbursement records mentioning PNH or
directly relevant activities in the Countdown to 2015
ODA+ data set.8 15 This data set includes ‘ofﬁcial devel-
opment assistance’ (ODA) and ‘private grants’, which
together we term ‘ODA+’. Other ofﬁcial ﬂows were
excluded. Records for the Countdown database were
obtained from the Organisation for Economic
Co-operation and Development’s (OECD) Creditor
Reporting System (CRS) aid activity database on 15
January 2015 for the years 2003–2013 and from the
Vaccine Alliance (GAVI) on its disbursements between
2003 and 2006, as the latter were missing from the CRS.15
Data cover disbursements from 31 high-income donor
Key questions
Recommendations for policy
▸ Our findings support the importance of global goals for mobi-
lising resources and catalysing change. Implementation and
monitoring of the Every Newborn Action Plan and the neonatal
target within the Sustainable Development Goals (SDGs), as
well as more focus on stillbirths, which still have no SDG
target, are essential.
▸ Effective mechanisms are needed to hold donors to account
for high-quality, timely and transparent reporting, and to
ensure that data systems are available to support this.
2 Pitt C, et al. BMJ Glob Health 2017;2:e000205. doi:10.1136/bmjgh-2016-000205
BMJ Global Health
group.bmj.com on October 23, 2017 - Published by http://gh.bmj.com/Downloaded from 
countries, 20 multilateral institutions, two global health
initiatives (GHIs), and one private foundation to 156
recipient countries. Each record contains data on the
year, donor, recipient and value of the disbursement, as
well as the project title and short and long descriptions
of the funded activities. The database avoids double-
counting by excluding donor countries’ core contribu-
tions to multilaterals (only counting these funds at the
time they are disbursed for speciﬁc activities by the mul-
tilaterals) and by attributing donor country funding for
a speciﬁed project to that donor, even if a multilateral
agency is contracted to deliver the project. The
Countdown coded each of these records according to an
activity-based framework to assess the value of non-
research funding for reproductive health, for maternal
and newborn health, and for child health. These cat-
egories also allow assessment of the value of MNCH and
of reproductive, maternal, newborn and child health
(RMNCH) as a whole.
Data coding
We identiﬁed records mentioning PNH in the entire
Countdown data set using an exhaustive key term search
followed by manual review and classiﬁcation of identi-
ﬁed records. We sought to include funding that men-
tioned the health of the newborn or fetus, or that
supported interventions in pregnancy or in the ﬁrst
4 weeks of life that are proven to improve or maintain
the health of the baby before, during, or in the ﬁrst
28 days following birth. In a previous analysis, we devel-
oped key terms by reviewing scientiﬁc literature; generat-
ing a list of general terms, conditions and diseases, and
interventions or programmes meeting our criteria; and
then carefully reﬁning our terms.12 For example, we
sought to include funding mentioning stillbirth, new-
borns, breastfeeding, or malaria or syphilis in pregnancy,
but to exclude funding for antenatal or obstetric care
unless it speciﬁcally mentioned the baby or PNH inter-
ventions. For this analysis, we revised and expanded the
previous set of key terms to increase the sensitivity of
our search. We conducted the search in Microsoft SQL
Server Management Studio (Microsoft Corporation,
2014) using 135 search terms in seven languages
(English, French, Dutch, Spanish, Portuguese, Italian,
German), and classiﬁed each term within a theme (web
table 1). We identiﬁed those of the 2.1 million records
in the Countdown database containing at least one of
our search terms in the project title, short description or
long description ﬁelds reported by donors.
We exported the subset of records identiﬁed by the
key terms to Excel for review and classiﬁcation. Records
with a blank or zero disbursement value were excluded.
CP and CG read and individually coded the remaining
records. First, records that were misclassiﬁed (as they did
not in any way support or mention prenatal or neonatal
health) were removed. Second, records were categorised
as supporting either (1) non-research or, (2) research
activities; this categorisation was made to allow direct
comparisons with the Countdown estimates of ODA+ for
RMNCH, which excludes research funding. As the CRS
database is a very incomplete source of data on research
funding, only those ﬁndings regarding non-research
funding are presented. Third, records were classiﬁed as
either (1) exclusively beneﬁting PNH, or (2) also bene-
ﬁting other population groups, such as mothers or chil-
dren older than 1 month. The purpose of this
categorisation was to examine the degree of integration
of PNH funding within the continuum of care16 and to
identify the minimum value of funding that could be
expected to beneﬁt PNH in practice; both categories are
presented in the analysis.
Data analysis
We present our ﬁndings in constant 2013 US$ and assess
trends over the 11-year period. We examined variation
in funding mentioning PNH over the 11-year period by
donor and recipient country. For our main analyses, we
present the full disbursement value of all relevant
records mentioning PNH and do not make assumptions
about the share of funding actually beneﬁting PNH. We
attribute the value of regional and unspeciﬁed bilateral
disbursements for PNH to recipient countries in propor-
tion to their receipt of country-speciﬁc funding for PNH
over the entire 2003–2013 period. We present disburse-
ments for each year in total and disaggregated by
whether the funding exclusively beneﬁtted PNH or also
beneﬁtted other population groups.
We then compare our ﬁndings to the Countdown esti-
mates of MNCH funding. Unlike our assessment of
PNH, Countdown applied a set of disbursement rules to
determine the proportion (0–100%) of the value of
each record considered to support MNCH.8 15 As a
result, for each record mentioning PNH, either the full
value of the disbursement or only part of the value of
the disbursement may be counted towards the
Countdown’s estimates of funding for MNCH.8
To explore the descriptions of funding mentioning
PNH, we classify each record mentioning PNH into at
least one of 16 themes, which reﬂect selected PNH inter-
ventions, target populations and causes of ill health.2 We
assigned records to themes using our main SQL search
terms as well as a few additional search terms in Excel
(web table 1).
To assess the degree of targeting to recipient coun-
tries’ need, we produced scatter plots and conducted
ordinary least squares regressions. For the scatter plots,
we compared total PNH funding and average funding
per live birth over the entire 2003–2013 period with the
NMR for the 143 of 156 recipient countries for which
NMR17 and World Bank income group data18 were avail-
able. We conducted these analyses for all funding men-
tioning PNH and for funding exclusively beneﬁtting
PNH. We used NMR data17 for 2008 as the independent
variable because the vast majority of PNH funding was
disbursed after this date (as we will show), and so we
take these data to reﬂect the information donors had
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regarding health needs at the time of most of their
funding decisions regarding PNH. To estimate average
funding per birth over the 11-year period, we divided
the total ODA+ for PNH received by each country in
each year by the total number of live births19 in that
country in the same year and then calculated the mean
of these ratios over the 11-year period for each country.
To illustrate recipient countries’ economic needs or cap-
acity to address their own health challenges, we colour-
coded each data point by World Bank income group.18
With our linear regression models, we sought to deter-
mine the degree to which health need (NMR in
200817), economic need (natural logarithm of 2008 per
capita gross domestic product (GDP)18), and the inter-
action of these two measures explained variation in our
dependent variable, the natural logarithm of cumulative
PNH funding over 2003–2013. We speciﬁed four models
with the outcome deﬁned as the natural logarithm of:
total ODA+ mentioning PNH, ODA+ mentioning PNH
per live birth, total ODA+ exclusively beneﬁtting PNH
and ODA+ exclusively beneﬁtting PNH per live birth.19
Both explanatory variables were centred by subtracting
the mean value from all observations to facilitate inter-
pretation. We conducted the analyses for the countries
in our data set (n=156) for which NMR (n=146), per
capita GDP (n=140), and live birth data (if needed)
(n=122) were available and for which the speciﬁed
outcome variable was >0 before the logarithmic trans-
formation. We repeated the analyses of funding per
birth for the countries within this set with median popu-
lations >250 000 over the period to check whether
extremely small countries, all of which received relatively
modest absolute levels of funding, affected the observed
ﬁndings. We also repeated the analyses excluding
extreme outliers. To check the appropriateness of our
variable transformations, we repeated the analyses
without the logarithmic transformations of per capita
GDP and of the outcome variables and also by adding a
value of one to all outcome values before the logarith-
mic transformations so as to allow inclusion in the
models of countries which received no PNH funding. As
all models displayed heteroscedasticity, we used
Huber-White estimators to generate robust SEs; other
model diagnostics were acceptable. The degree of target-
ing to need was assessed based on the sign and signiﬁ-
cance of the coefﬁcients on the independent variables
and the R2 value for each model.
RESULTS
Of the 2.1 million records in the Countdown database,
15 062 were identiﬁed by our searches as potentially
relevant to PNH. After removing 2957 records with
blank or zero disbursement values, 955 that were mis-
classiﬁed and 398 supporting PNH research activities,
10 752 non-research records mentioning PNH remained
for analysis.
The annual value of ODA+ mentioning PNH or an
activity that would directly beneﬁt PNH increased more
than 14-fold from $105 million in 2003 to $1465
million in 2013 (constant 2013 US$, ﬁgure 1A, web
table 2). ODA+ for PNH increased in every year until
2012 and more than doubled from $708 million in
2009 to a high of $1506 million in 2012, but declined
by 3% in 2013.
Almost all ODA+ mentioning PNH also beneﬁtted
other population groups; <1% exclusively beneﬁtted
PNH over the period and this proportion fell from over
2% in 2003 to <0.5% in 2013. ODA+ exclusively beneﬁt-
ting PNH tripled from just $2 million in 2003 to $6
million in 2013 (ﬁgure 1, web table 2). In 2010, this
ODA+ exclusively beneﬁtting PNH hit a high of over $11
million, but decreased to $5 million, $7 million and $6
million in the subsequent 3 years.
In ﬁgure 1B, we examine ODA+ mentioning and
exclusively beneﬁting PNH within ODA+ for MNCH,
which was estimated to have increased nearly 2.5-fold
from $2708 million in 2003 to $9287 million in 2013.8
As ODA+ exclusively beneﬁtting PNH represented just
0.09% of ODA+ for MNCH over the whole period, it is
barely visible in the ﬁgure. In contrast, records mention-
ing PNH and beneﬁtting others accounted for 9% of
the total value of aid to MNCH over the period, and
increased from 3% in 2003 to 13% in 2013. The value of
ODA+ for MNCH that mentioned PNH increased
15-fold between 2003 and 2013, much faster than the
2.5-fold increase in ODA+ for MNCH as a whole. Both
values increased in every year from 2003 to 2012;
however, from 2012 to 2013 ODA+ for MNCH increased
by a further 14%, while the value of ODA+ for MNCH
that mentioned PNH fell by 13%. Funding for PNH for
the 75 Countdown priority countries showed a similar
trend, with an 18-fold increase overall, but a 20-fold
increase between 2003 and 2012 and a 9% drop
between 2012 and 2013.
Most ODA+ mentioning PNH did not contain any key
terms allowing more precise classiﬁcation of the speciﬁc
activities, health conditions or level(s) of the health
system targeted. (Table 2) More than three-quarters of
ODA+ mentioning PNH included generic terms related
to newborns, such as ‘neonatal’. Terms speciﬁc to breast-
feeding were used in descriptions for 12% of the value
of ODA+ for PNH; most of these were funded through
Unicef and did not mention a speciﬁc focus on early,
exclusive breastfeeding, which would beneﬁt newborns.
Of the 1423 records mentioning breastfeeding, 64
(valued at $15 million across the period) focused exclu-
sively on newborns and mentioned breastfeeding along-
side other activities speciﬁcally for the newborn. Terms
related to neonatal tetanus prevention ($284 million,
4.0%), neonatal resuscitation ($40 million, 0.6%), birth
weight ($32 million, 0.5%), preterm birth ($20 million,
0.3%) and umbilical cord care ($15 million, 0.2%) were
also mentioned in PNH funding descriptions across the
11 years.
4 Pitt C, et al. BMJ Glob Health 2017;2:e000205. doi:10.1136/bmjgh-2016-000205
BMJ Global Health
group.bmj.com on October 23, 2017 - Published by http://gh.bmj.com/Downloaded from 
Figure 1 ODA+ for prenatal and neonatal health, 2003–2013, from 54 donors to 156 recipient countries. (A) Presents the full
disbursement value of non-research ODA+ mentioning PNH, broken down by whether the funding exclusively benefitted PNH or
also benefitted other population groups. It also illustrates how the funding mentioning PNH was categorised within the
Countdown framework for estimating the value of funding for maternal, newborn and child health (MNCH). For each record
mentioning PNH, between 0% and 100% of the full value of the disbursement may be counted towards the Countdown’s
estimates of funding for ‘maternal and newborn health’ (MNH) or ‘child health’. (B) presents ODA+ for MNCH based on estimates
produced by the Countdown to 2015;8 within these estimates are highlighted the value of funding from records which exclusively
benefitted PNH and those which mention PNH but also benefit others. ODA+, official development assistance plus private grants;
PNH, prenatal and neonatal health.
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Among the records analysed, only two, valued at $3
million, directly mentioned stillbirth or related terms in
its descriptions (table 1). Another project, valued at
$24,000 mentioned miscarriage. The fetus was men-
tioned in six records valued at $3 million. In contrast,
malaria in pregnancy, which accounts for 8.2% of all
stillbirths (∼220 000 per year) and is the leading cause
of stillbirths in sub-Saharan Africa,1 was mentioned in
projects worth $800 million globally. While all projects
mentioning malaria in pregnancy were included in
our estimate of ODA+ for PNH, none explicitly men-
tioned stillbirth, miscarriage or the fetus. Only 38 pro-
jects, valued at $31 million, mentioned syphilis, which
accounts for 7.7% of global stillbirths; of these, 10
also mentioned newborns, although none mentioned
stillbirth, miscarriage or the fetus, even though early
fetal deaths and stillbirths from syphilis outnumber
neonatal deaths from syphilis by more than two to
one.20
Over the 11-year period, two donors together
accounted for 56% of all ODA+ mentioning PNH: the
USA ($2848 million, 40%) and Canada ($1198 million,
17%). They were followed by the World Bank’s
International Development Association (IDA, $585
million, 8%), the Global Fund ($522 million, 7%) and
the UK ($453 million, 6%) (table 2). The leading
donors of ODA+ exclusively beneﬁtting PNH were
Unicef ($18 million, 30%), the USA ($15 million, 25%),
Japan ($5 million, 8%) and the UK ($4 million, 6%).
All ODA from Canada, the IDA and the Global Fund
that mentioned PNH supported activities that would also
beneﬁt other population groups, as did 99% of ODA
from the UK and the USA. Canada provided nearly all
of its funding mentioning PNH in 2011–2013, when it
disbursed $301 million, $282 million and $286 million,
respectively. The UK’s funding increased substantially in
2012 and 2013, when it disbursed $180 million and
$132 million, respectively. Together, bilateral donors
accounted for 66% of ODA+ exclusively beneﬁtting
PNH and 74% of funding also beneﬁtting others. The
UK, Sweden and Australia all substantially increased
their ODA+ mentioning PNH in 2012 but then
decreased their funding in 2013 by a combined total of
$107 million, which more than accounted for the
Table 1 Funding for prenatal and neonatal health (PNH) by thematic area, 2003–2013
Theme
Exclusively benefits PNH Mentions PNH and others Total mentioning PNH
Number of
records Value
Per
cent
Number of
records Value
Per
cent
Number of
records Value
Per
cent
Newborn (generic) 524 53.6 91 8280 5426.0 76 8804 5479.6 76
Breastfeeding 64 14.7 25 1359 859.9 12 1423 874.5 12
Malaria in
pregnancy
0 0.0 0 498 800.3 11 498 800.3 11
MNCH 0 0.0 0 305 550.0 8 305 550.0 8
Neonatal tetanus 2 0.6 1 346 283.2 4 348 283.8 4
Postnatal (generic) 0 0.0 0 325 251.6 4 325 251.6 4
Perinatal (generic) 14 5.1 9 169 130.8 2 183 135.9 2
Neonatal
resuscitation
64 14.7 25 21 24.8 0 85 39.5 1
Birth weight 63 14.7 25 40 17.7 0 103 32.4 0
Syphilis 0 0.0 0 38 31.5 0 38 31.5 0
Preterm birth 71 15.5 26 9 4.7 0 80 20.2 0
Umbilical cord 64 14.9 25 3 0.1 0 67 15.0 0
Fetus (generic) 2 0.2 0 4 2.7 0 6 2.9 0
Stillbirth 1 0.5 1 1 2.4 0 2 2.9 0
Kangaroo mother
care
0 0.0 0 2 1.2 0 2 1.2 0
Birth asphyxia 0 0.0 0 0 0.0 0 0 0.0 0
Jaundice 0 0.0 0 0 0.0 0 0 0.0 0
Miscarriage 0 0.0 0 1 0.0 0 1 0.0 0
Total 539 58.8 100 10 213 7116.7 100 10 752 7175.5 100
Total value of funding (constant 2013 US$ millions) provided over the period 2003–2013. Themes are not mutually exclusive, so columns sum
to more than 100%. Search terms used to classify records into themes are provided in web table 1.
MNCH, maternal, newborn and child health (this category reflects those projects identified by this abbreviation or its equivalent in other
languages).
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Table 2 Funding mentioning prenatal and neonatal health (PNH) by donor, 2003–2013
Rank Donor Exclusively benefits PNH Mentions PNH and others Total
1 USA 14.7 2833.8 2848.5
2 Canada 0.0 1198.3 1198.3
3 World Bank International Development Association 0.0 584.9 584.9
4 Global Fund for AIDS, Tuberculosis and Malaria 0.0 522.2 522.2
5 UK 3.6 449.2 452.9
6 Australia 0.5 193.8 194.3
7 Bill & Melinda Gates Foundation 2.2 191.5 193.8
8 UN Population Fund (UNFPA) 0.0 169.5 169.5
9 Asian Development Bank Special Fund 0.0 157.6 157.6
10 Norway 1.0 112.5 113.5
11 Sweden 0.0 102.9 103.0
12 European Union Institutions 0.1 92.5 92.6
13 UN Children’s Fund (Unicef) 17.7 68.8 86.6
14 The Vaccine Alliance (GAVI) 0.0 66.7 66.7
15 Spain 3.8 55.1 58.9
16 Japan 4.7 51.0 55.7
17 Netherlands 0.0 49.5 49.5
18 France 0.1 45.0 45.1
19 Switzerland 3.4 34.5 37.9
20 Korea 1.0 24.6 25.7
21 Belgium 1.9 21.9 23.8
22 Germany 0.2 21.8 22.1
23 World Bank International Development Bank Special Fund 0.0 14.6 14.6
24 Luxembourg 1.2 10.8 12.0
25 Italy 2.3 6.6 8.9
26 Denmark 0.0 8.4 8.4
27 WHO 0.0 6.5 6.5
28 New Zealand 0.0 5.6 5.6
29 OPEC Fund for International Development 0.0 5.2 5.2
30 Finland 0.0 4.2 4.2
31 Iceland 0.0 2.4 2.4
32 UNAIDS 0.0 1.4 1.4
33 United Arab Emirates 0.0 1.3 1.3
34 Portugal 0.0 0.8 0.8
35 Ireland 0.0 0.7 0.7
36 Greece 0.2 0.0 0.2
37 Austria 0.0 0.2 0.2
38 Czech Republic 0.0 0.2 0.2
39 Poland 0.0 0.2 0.2
40 Slovak Republic 0.0 0.1 0.1
41 UN Development Programme (UNDP) 0.0 0.1 0.1
Total 58.8 7116.7 7175.5
The table presents the total value of non-research funding (constant 2013 US$ millions) mentioning PNH provided by each donor over the
period 2003–2013, by whether the funding exclusively benefitted PNH or also benefitted other population groups. Donors are ranked from
highest to lowest total disbursements. Of the 54 donors in the Countdown database, 13 did not provide any non-research funding mentioning
PNH in 2003–2013 period and so do not appear in this table: Estonia, Kuwait, Slovenia, African Development Bank, African Development Fund,
Arab Fund for Economic and Social Development, Arab Fund for Economic Development in Africa (BADEA), Global Environment Facility,
United Nations Refugee Agency (UNHCR), United Nations Peacebuilding Fund, International Monetary Fund (Concessional Trust Funds) and
the World Food Programme. Donors appearing in the table with a total disbursement showing as ‘$0.0 million’ disbursed <$50 000, which was
rounded down. There is no double-counting of bilateral and multilateral ODA and private grants, so the columns sum to 100%.
OPEC, Organization of the Petroleum Exporting Countries; PNH, prenatal and neonatal health; UN, United Nations.
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overall $40 million decline in ODA+ mentioning PNH
in 2013.
Funding for PNH also varied substantially by recipi-
ent country (ﬁgures 2 and 3, web tables 3 and 4). All
156 recipient countries in the Countdown ODA+ data-
base received funding supporting MNCH, while 125
received ODA+ mentioning PNH and 100 received
funding exclusively beneﬁtting PNH. The 75
Countdown priority countries together received 91% of
all ODA+ for PNH and this proportion remained rela-
tively consistent over the period. The recipients of the
most ODA+ mentioning PNH were Afghanistan ($667
million including regional allocations), Pakistan ($572
million), Bangladesh ($375 million), Ethiopia ($364
million) and India ($356 million). Taking population
sizes into account, the leading recipients of ODA+ for
PNH per birth tended to be much smaller countries:
Belize ($131 per birth), Fiji ($99 per birth), Haiti ($68
per birth), Zimbabwe ($60 per birth), Afghanistan ($60
per birth) and Nicaragua ($58 per birth). India
received $8 million in ODA+ exclusively beneﬁtting
PNH, followed by Mozambique ($4.3 million), Pakistan
($3.7 million) and Mali ($3.4 million); only 14 coun-
tries received more than $1 million for projects exclu-
sively beneﬁtting PNH across the period. With $1.08
per birth, the West Bank and Gaza Strip received the
largest volume of funding exclusively beneﬁtting PNH,
but could not be included in our scatter plots or regres-
sions because NMR data was unavailable. It was fol-
lowed by Laos ($0.62 per birth), Ukraine ($0.60 per
birth), Uruguay ($0.58 per birth) and Mali ($0.46 per
birth).
Figure 2 Maps: Variation by recipient country in ODA+ mentioning PNH in total and per live birth, 2003–2013. (A) Presents
variation in total ODA+ mentioning PNH by recipient country. (B) Presents variation in ODA+ mentioning PNH per birth by
recipient country. Data are presented in constant 2013 US$ and were prepared in ArcGIS V.10.3. ODA+, official development
assistance plus private grants; PNH, prenatal and neonatal health.
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Funding mentioning PNH was somewhat targeted to
countries with greater need, but there was less evidence
that funding exclusively beneﬁtting PNH was targeted to
need (web table 5). The four scatter plots show the weak
association between our metric of health need, NMR,
and the value of funding mentioning PNH and exclu-
sively beneﬁtting PNH in total and per birth (ﬁgure 3).
The multivariable regression analyses indicated that
Figure 3 Targeting of ODA+ mentioning prenatal and neonatal health (PNH) to countries with the greatest need, 2003–2013.
The four scatter plots present the association between the amount of official development assistance and private grants (ODA+)
received by each country and the neonatal mortality rate (our metric of health needs) in that country. Data points are
colour-coded by country income group to provide an indication of their economic need. The four scatter plots show total funding
over the 11-year period (plots A and B) and average ODA+ per birth (plots C and D) that mentions PNH (plots A and C) and that
exclusively benefits PNH (plots B and D).
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countries with lower per capita GDP and higher NMR
tended to receive more ODA+ mentioning PNH;
however, while the negative relationship with per capita
GDP was strongly signiﬁcant in the total ODA+
(p<0.001) and per birth (p<0.001) models, the positive
relationship with NMR was only weakly signiﬁcant in the
per birth model (p=0.058) and not signiﬁcant in the
total ODA+ model (p=0.107). Both models demon-
strated high goodness of ﬁt, although total ODA+ men-
tioning PNH appeared better targeted to health and
economic need (R2=0.47) than ODA+ per birth
(R2=0.35). For funding exclusively beneﬁting PNH,
there was less evidence of targeting to need: the negative
association with per capita GDP was strong in both the
total ODA+ model (p=0.021) and the per birth model
(p<0.001), but the association with NMR was not signiﬁ-
cant and negative in the total ODA+ model (p=0.664)
and weak and positive in the per birth model (p=0.054).
The goodness of ﬁt was poor in the total ODA+ model
(R2=0.08) but reasonable in the per birth model
(R2=0.29) and both were lower than in the models of
ODA+ mentioning PNH. When we reran the analyses
under alternative model speciﬁcations, the signiﬁcant,
negative relationship with per capita GDP remained in
all models, as did the lack of signiﬁcant relationship
between NMR and total ODA+ mentioning or exclu-
sively beneﬁtting PNH; however, some speciﬁcations of
the per birth models indicated a moderately signiﬁcant,
positive relationship with NMR while other speciﬁcations
indicated that the relationship was not signiﬁcant (web
table 5).
DISCUSSION
We found substantial increases in the value of donor
funding mentioning PNH between 2003 and 2013 in
absolute terms and relative to funding for MNCH as a
whole. We interpret these ﬁndings as reﬂecting a sub-
stantial rise in attention for newborn health on the
global agenda, particularly from 2008. Nonetheless,
funding exclusively beneﬁtting PNH remained extremely
low, reaching just $6 million in 2013 of a total of more
than $9 billion disbursed for MNCH. From 2012 to
2013, funding mentioning PNH and exclusively beneﬁt-
ting PNH decreased, even though funding for MNCH
increased by 14%. The USA and Canada provided over
half of funding mentioning PNH over the period; with
the rise to power of Donald Trump and the departure of
Prime Minister Stephen Harper, who personally cham-
pioned RMNCH within the G8, this funding may be
subject to political changes. We argue that these ﬁndings
indicate a need for caution and continued monitoring
of donors’ support for newborn health. Consistent with
previous ﬁndings,11 12 we found that prenatal health,
including stillbirth, continued to receive minimal atten-
tion in donors’ descriptions of their programmatic
funding relative to its burden. Some donors have expli-
citly prioritised PNH to a greater extent than others; the
list of leading donors mentioning PNH in their funding
records shares commonalities with, but is by no means
the same as, the leading donors for RMNCH as a
whole.8 Canada, in particular, is much more highly
ranked for PNH funding than for overall RMNCH
funding, although none of its funding exclusively bene-
ﬁted newborn health and stillbirth prevention. Most
Countdown priority countries received <$1 million in
funding even mentioning PNH across the entire 11-year
period. We found evidence of targeting of funds men-
tioning PNH to countries with lower GDP per capita,
but there was inconsistent evidence of targeting based
on NMR, and less evidence that funding exclusively
beneﬁtting newborns was targeted to need.
The actual value of funding that ultimately beneﬁts
PNH could be nearly as low as the value of funding
exclusively beneﬁtting PNH ($6 million in 2013) or
nearly as high as the value of funding beneﬁtting
MNCH as a whole ($9287 million in 2013). While much
of the funding for maternal health could and should
also beneﬁt PNH even if PNH is not mentioned directly,
the slower progress in reducing neonatal mortality and
stillbirth rates relative to postneonatal and maternal mor-
tality indicates that the beneﬁts to PNH from maternal
and particularly from child health funding cannot be
assumed.6 Funding focused on PNH may therefore play
an important role in ensuring that the 5.3 million still-
births and neonatal deaths receive due attention within
programmes. Funding mentioning PNH that is also
intended to beneﬁt other population groups may be
more likely to beneﬁt PNH than maternal and child
health programmes which do not mention PNH, but
this is not clear, especially for those where the mention
is just part of the term ‘maternal, newborn and child
health’. In practice, it is uncertain whether babies actu-
ally beneﬁt from maternal and child health programmes
and even wider primary healthcare, hospital and health
systems support, regardless of whether PNH is men-
tioned in funding summaries. In some programmes,
implementers may be able to inﬂuence the focus of
broader investments, but in others, such as large immun-
isation programmes, the investments are very ﬁxed. For
example, even investments in care at birth or more mid-
wives would not necessarily reduce stillbirths or neonatal
deaths if key skills or equipment, such as fetal monitor-
ing during labour and neonatal resuscitation are not
included. Conversely, programmes addressing malaria or
syphilis in pregnancy rarely mention stillbirths and yet
may make their greatest impact through stillbirth pre-
vention. We also have no information on the relative efﬁ-
ciency with which funds are used and translated into
population-level beneﬁts in different settings and over
time.
While we found an 18-fold increase in the value of
MNCH funding mentioning PNH between 2003 and
2012 for the Countdown priority countries, this is only
half the 34-fold increase previously reported for the
same period.13 In contrast, we found a 10-fold increase
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in the total value of funding mentioning PNH for all
recipients between 2003 and 2010, which is slightly
higher than the nearly ninefold increase previously
reported for that period.12 Most of the changes in our
estimates from those previously published reﬂect donors
adding retrospective data, which led to increases in their
funding estimates for past years. Several of our methodo-
logical improvements, notably our inclusion of a relevant
proportion of regional and unspeciﬁed funding within
country-speciﬁc estimates, led to increases relative to
previous estimates; however, the effects of these changes
were eclipsed by donors’ retrospective amendments to
their data. While such amendments should be encour-
aged, they underscore the importance of holding
donors to account for high-quality, timely and transpar-
ent reporting21 and of ensuring that data systems are
available to support this.
The CRS database—on which the Countdown to
2015 ODA+ is based—has several advantages, including
its consistent and comparable reporting framework,
which avoids double-counting of funds disbursed from
countries to multilateral institutions and global health
initiatives, as well as the fact that the donors themselves
report and agree all funding reported. Nonetheless,
the CRS also has a number of disadvantages, notably
the lack of reports from China, Brazil, some other
donor countries, and all but one private foundation,
and its sector and purpose code classiﬁcation system,
which does not facilitate the identiﬁcation of funding
for different types of health activities, beneﬁciary
groups, or health conditions, such as PNH.12 Our
approach of ﬁrst implementing a sensitive key term
search and then individually reading and coding pro-
jects for this analysis was both efﬁcient and, we believe,
a reasonably accurate and precise method for max-
imally exploiting the available data and overcoming
some of the serious limitations of the sector and
purpose code framework in the CRS database. Such
combinations of automated and human coding could
prove a useful approach to enable aid tracking for spe-
ciﬁc issues and should be considered as new mechan-
isms are established to hold donors accountable for
their obligations and commitments in the SDG era.22
These ﬁndings must therefore be interpreted with the
caveats given; however, they have important policy impli-
cations. Our ﬁndings build on our past analyses,12 13
providing further quantitative evidence of the rise of
newborn health on the global agenda, and the contin-
ued neglect of stillbirths and prenatal health in pro-
grammatic funding more generally.4 11 Future research
should examine why some countries receive so much
more funding mentioning PNH than others and
whether differences in funding descriptions are asso-
ciated with differences in programme implementation.
We argue that our ﬁndings support the importance of
global goals for mobilising resources and attention and
catalysing change. Implementation and monitoring of
the Every Newborn Action Plan23 and the neonatal
target within the SDGs, as well as more focus on still-
births, which still have no SDG target, are essential,4
especially in light of the apparent reductions in 2013.
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